HAMBURG, Germany and OXFORD, England, August 28 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) is pleased to invite you to a webcast presentation and conference call on detailed Phase II data for its lead compound EVT 201 in the treatment of insomnia on 5 September 2007 at 11.00 am CET / 10.00 am GMT / 5.00 am EST / 7.00 pm AEST
The Evotec speakers at the worldsleep07 congress and in the webcast and conference call will be:
- Dr John Kemp, Chief Research and Development Officer
- Dr Tim Tasker, Executive Vice President Clinical Development
Evotec will host a poster presentation on the study results at the worldsleep07 congress from 4.00 to 6.00 pm AEST time at the Sofitel Reef Hotel, 35-41 Wharf Street, Cairns, Australia (poster No PO649). Following the conference presentation, Evotec will hold the webcast and conference call to discuss the results. Positive headline results of this first Phase II study in 67 patients were released on 4 June 2007.
To attend the webcast and conference call, please dial in using the following phone numbers:
PIN code: 5301349
Please dial in 10 minutes before the beginning of the conference.
The presentation will be available at the Evotec homepage http://www.evotec.com.
Evotec expects the results from a second Phase II study in 135 elderly insomniacs to be available in October 2007.
Although certain aspects of insomnia are addressed by current treatments, there is no drug yet available which meets all the needs of insomnia patients.
About EVT 201
EVT 201 is a partial positive allosteric modulator (pPAM) of the GABAA
receptor complex. Acting on GABAA receptors it addresses the gold standard
|SOURCE Evotec AG|
Copyright©2007 PR Newswire.
All rights reserved